EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers-Reference-Cited by-同舟云学术

EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

Published:2014-08-20 Issue:1 Volume:29 Page:23-29
ISSN:0268-8697
Container-title:British Journal of Neurosurgery
language:en
Short-container-title:British Journal of Neurosurgery

Author:

Faulkner Claire,Palmer Abigail,Williams Hannah,Wragg Christopher,Haynes Harry R.,White Paul,DeSouza Ruth-Mary,Williams Maggie,Hopkins Kirsten,Kurian Kathreena M.

Publisher

Informa UK Limited

Subject

Clinical Neurology,General Medicine,Surgery

Link

http://www.tandfonline.com/doi/pdf/10.3109/02688697.2014.950631

Reference39 articles.

1. EGF mutant receptor vIII as a molecular target in cancer therapy.

2. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

3. IDH1andIDH2Mutations in Gliomas

4. Epidermal growth factor receptor

5. Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-based therapeutic targets in pediatric high-grade glioma;2024-08-28

2. Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023);Human Vaccines & Immunotherapeutics;2024-05-02

3. Principles in the Management of Glioblastoma;Genes;2024-04-17

4. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children’s Oncology Group Study;Neuro-Oncology Advances;2024-01-01

5. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11